omalizumab (Xolair) and chronic spontaneous urticaria. Too many adverse effects and uncertainties.

Omalizumab has only modest and transient symptomatic efficacy when an antihistamine is ineffective. Its adverse effects can be severe, and its safety during long-term use is uncertain. Omalizumab is not better than a corticosteroid.